Results from a recent study published in the Journal of the American Medical Association, showed that omega-3 supplements did not slow cognitive decline in 4,000 older patients that were followed over a five-year period. These results are divergent with some evidence indicating that a diet high in…
Results from a recent study published in the Journal of Neurology Neurosurgery & Psychiatry revealed nine possibly modifiable risk factors that may contribute towards up to two thirds of all cases of Alzheimer’s disease (AD) worldwide. However, the results also suggest that AD is a complex condition with many risk…
In a recent study published in the journal Alzheimer’s & Dementia a team of researchers found that eating a group of certain foods known as the MIND diet may slow cognitive decline among aging adults, even when the person is not at risk of developing Alzheimer’s…
Soon-to-be former partners in a promising Alzheimer’s research program, Eli Lilly and Co. and the University of California San Diego (UCSD) have moved a step closer to ending the contract that covers the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study, a groundbreaking clinical trial that aims to test solanezumab. This Phase…
In a recent study published in the International Journal of Geriatric Psychiatry, a team of researchers from the ECU’s Centre of Excellence for Alzheimer’s Research and Care at Edith Cowan University have found a strong association between depressive symptoms and cognitive decline. In the study titled “…
In a recent study published in Angewandte Chemie, a team of researchers from the University of Melbourne have identified that a specific protein known for its involvement in the progression of Alzheimer’s disease (AD) has properties that could be beneficial for human health. The study findings may help…
Last week, the Alzheimer’s Association gave much-deserved recognition to a pair of not-for-profit foundations for their dedication in supporting biomedical research on Alzheimer’s Disease. The Association selected the MetLife Foundation and GHR Foundation to receive the Jerome H. Stone Philanthropy Award for Alzheimer’s Research, which was awarded during this year’s Alzheimer’s Association International…
Accera, Inc. a clinical-stage biotechnology company based in Broomfield, Colorado, recently announced that 75% of patients have been enrolled in its NOURISH AD Phase 3 clinical trial assessing the efficacy of its investigational compound AC-1204 for the treatment of Alzheimer’s disease (AD). The company is expecting to enroll a total…
Brandywine Senior Living, a leading provider of quality care and services to seniors, has just partnered with the Alzheimer’s Association Delaware Valley Chapter to remind its residents living with this neurodegenerative disease of the joy of listening to music. Thanks to generous funding from the Association, residents will soon rediscover the…
Piramal Imaging recently announced that it will present nine studies on the effects of Neuraceq (florbetaben F18 injection) at the Alzheimer’s Association International Annual Conference (AAIC), July 18-23, 2015 at the Walter E. Washington Convention Center in Washington, D.C. Neuraceq is indicated for Positron Emission Tomography (PET) imaging of…
Get regular updates to your inbox.